This year’s EMBO Gold Medal is going to two researchers who study cell metabolism, Sarah-Maria Fendt and Markus Ralser.
Category: Press releases
“Mini brain” organoids show potential for SARS-CoV2 to cause neurodegenerative- disease-like effects
New research published yesterday in The EMBO Journal reports that the SARS-CoV-2 coronavirus can target human neurons with the potential to cause disease of the central nervous system (CNS). The research showed that the virus can enter tiny laboratory-developed 3D structures called brain organoids that replicate key aspects of the human brain and induce pathological effects similar to early stages of diseases of the CNS such as Alzheimer’s.
Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies.
EMBO announces an extension of its current Short-Term Fellowship scheme: Core Facility Fellowships. These fellowships will support exchanges of technology and expertise between core research facilities that provide services to research institutions or universities.
EMBO and FEBS announce Elly Tanaka of the Research Institute of Molecular Pathology, Vienna BioCenter, Austria, as the recipient of the FEBS | EMBO Women in Science Award 2020.
EMBO is pleased to announce that eleven life scientists have been selected to receive Installation Grants, which will support them in establishing independent laboratories in the Czech Republic, Poland, Portugal and Turkey.
Multi-journal partnership aims to accelerate scientific publishing by offering journal-independent peer review
MALT1 blockers have long been in clinical use for the treatment of blood cancers. A study suggests that these drugs could potentially also be developed as a treatment option for glioblastoma, the most common and lethal type of brain tumour.